Drugs

pp 1–10 | Cite as

Eculizumab: A Review in Generalized Myasthenia Gravis

Adis Drug Evaluation
  • 74 Downloads

Abstract

The humanized monoclonal antibody eculizumab (Soliris®) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan. It is the first complement inhibitor to be approved for use in these patients. In the well-designed, 26-week REGAIN study in patients with anti-AChR-positive refractory gMG, although a statistically significant benefit of eculizumab over placebo in the prespecified primary endpoint analysis (change from baseline in MG-activities of daily living (ADL) score assessed by worst-rank ANCOVA) was not formally demonstrated, preplanned and post hoc sensitivity analyses of this outcome, as well as other secondary outcomes supported the efficacy of eculizumab. Overall, patients receiving eculizumab experienced significant improvements in the ADL, muscle strength and health-related quality of life (HR-QOL) parameters relative to patients receiving placebo. Moreover, an ongoing extension of REGAIN showed that treatment benefits with eculizumab were sustained during continued therapy for at least 52 weeks. Eculizumab was generally well tolerated in these studies, with a tolerability profile similar to that reported previously in other indications. Although several questions remain, such as duration of treatment, cost effectiveness and long-term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gMG.

Notes

Acknowledgements

During the peer review process, the manufacturer of eculizumab (Soliris®) was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Sohita Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/39FCF0602D6721C2.

References

  1. 1.
    Tuzun E, Huda R, Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun. 2011;37(2):136–43.CrossRefPubMedGoogle Scholar
  2. 2.
    Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473–94.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90–100.CrossRefPubMedGoogle Scholar
  5. 5.
    Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427–38.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    National Institute of Neurological Disorders and Stroke. Myasthenia gravis fact sheet. 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Myasthenia-Gravis-Fact-Sheet#3. Accessed 8 Jan 2018.
  7. 7.
    Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175(3):408–18.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Huda R, Tuzun E, Christadoss P. Targeting complement system to treat myasthenia gravis. Rev Neurosci. 2014;25(4):575–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis: results from population based cohorts. Health Qual Life Outcomes. 2015;13:115.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167–78.CrossRefPubMedGoogle Scholar
  11. 11.
    Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255–60.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–25.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267–80.PubMedGoogle Scholar
  14. 14.
    Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology. 1993;43(6):1167–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhou Y, Gong B, Lin F, et al. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol. 2007;179(12):8562–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Alexion Pharmaceuticals Inc. Soliris (eculizumab): US prescribing information. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s422lbl.pdf. Accessed 10 Nov 2017.
  17. 17.
    Alexion Europe SAS. Soliris (eculizumab): summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf. Accessed 11 Nov 2017.
  18. 18.
    Japan Ministry of Health Labour and Welfare. Soliris (eculizumab): Japanese prescribing information. 2017. http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/T171226I0050.pdf. Accessed 10 Jan 2018.
  19. 19.
    Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73(18):2053–66.CrossRefPubMedGoogle Scholar
  20. 20.
    McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–45.CrossRefPubMedGoogle Scholar
  21. 21.
    Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17–18):1389–401.CrossRefPubMedGoogle Scholar
  22. 22.
    Schatz-Jakobsen JA, Zhang Y, Johnson K, et al. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J Immunol. 2016;197(1):337–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Lathia C, Gao X, Kassir N, et al. Population pharmacokinetic and pharmacodynamic analysis of eculizumab to support phase III dosing regimen in patients with refractory generalized myasthenia gravis [abstract no. PII-091]. Clin Pharmacol Ther. 2015;97(Suppl 1):S87.Google Scholar
  24. 24.
    Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017.  https://doi.org/10.1016/S1474-4422(17)30369-1.PubMedGoogle Scholar
  25. 25.
    Howard J, Wang JJ, O’Brien F, et al. Efficacy of eculizumab on myasthenia gravis-activities of daily living and its respiratory, bulbar, limb and ocular domains in patients with ACHR+ refractory generalized myasthenia gravis [abstract no. 210 and poster]. Muscle Nerve. 2017;56(3):106.Google Scholar
  26. 26.
    Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76–84.CrossRefPubMedGoogle Scholar
  27. 27.
    European Medicines Agency. Soliris (eculizumab): CHMP extension of indication variation assessment report. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000791/WC500233876.pdf. Accessed 10 Nov 2017.
  28. 28.
    Muppidi S. The myasthenia gravis: specific activities of daily living profile. Ann NY Acad Sci. 2012;1274:114–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Katzberg HD, Barnett C, Merkies IS, et al. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve. 2014;49(5):661–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann NY Acad Sci. 2012;1274:99–106.CrossRefPubMedGoogle Scholar
  31. 31.
    Burns TM, Grouse CK, Conaway MR, et al. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010;41(2):219–26.PubMedGoogle Scholar
  32. 32.
    Howard J, O’Brien F, Wang JJ, et al. Dual responder analyses of both muscle strength and activities of daily living, eculizumab versus placebo, in refractory generalized myasthenia gravis (gMG) patients: results from the REGAIN study [abstract no. 012]. Neurology. 2017;88(19 Suppl).Google Scholar
  33. 33.
    Andersen H, Mantegazza R, Derosier F, et al. Eculizumab improves fatigue in patients with refractory generalized myasthenia gravis in the REGAIN study [abstract no. PR1094]. Eur J Neurol. 2017;24(Supp 1):498.Google Scholar
  34. 34.
    Andersen H, Mantegazza R, Derosier F, et al. Correlation of neuro-QOL with MG-ADL, QMG, and MG-QOL15 in assessing the spectrum of disease in patients with refractory generalised myasthenia gravis in the REGAIN study [abstract no. PR1095]. Eur J Neurol. 2017;24(Supp 1):498–9.Google Scholar
  35. 35.
    Howard J, Wang JJ, O’Brien F, et al. Efficacy of eculizumab is maintained beyond 26 weeks in patients with AChR+ refractory generalized myasthenia gravis [abstract no. 211 plus poster]. Muscle Nerve. 2017;56(3):106.Google Scholar
  36. 36.
    Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol. 2015;15(3):199–206.CrossRefPubMedGoogle Scholar
  37. 37.
    Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2016;13(1):118–31.CrossRefPubMedGoogle Scholar
  38. 38.
    Gilhus NE. Eculizumab: a treatment option for mysthenia gravis? Lancet Neurol. 2017.  https://doi.org/10.1016/S1474-4422(17)30363-0.PubMedGoogle Scholar
  39. 39.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations